-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2023-506962-30-00
5
2021-03-29
Non-alcoholic steatohepatitis (NASH)
-
2023-506526-37-00
5
2021-03-17
Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
2022-502600-79-00
4
2021-03-16
Endometrial cancer
-
2022-502705-15-00
5
2021-03-08
High-risk muscle-invasive bladder cancer
-
2023-507890-17-00
5
2021-02-22
Anemia associated with myeloproliferative neoplasm (MPN)-associated my
-
2024-512354-21-00
4
2021-02-22
Newly diagnosed multiple myeloma
-
2022-503072-84-00
5
2021-02-13
stage IIIa cardiac AL amyloidosis
-
2023-507475-21-00
10
2021-01-18
Lung Cancer, Non-Small Cell
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2023-506911-16-00
5
2020-12-04
ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
-
2022-502611-10-00
5
2020-11-24
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-509171-16-00
5
2020-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
-
2023-506877-37-00
5
2020-09-28
Relapsed/Refractory Multiple Myeloma
-
2024-513422-38-00
5
2020-09-28
Newly diagnosed multiple myeloma
-
2022-501522-38-00
5
2020-09-04
Chronic lymphocytic leukemia; Non-Hodgkin's lymphoma; Multiple Myeloma
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2023-507419-37-00
5
2020-06-25
Plasma cell myeloma
-
2023-508962-14-00
5
2020-06-18
Relapsed/Refractory Multiple Myeloma
-
2023-508214-42-00
5
2020-05-25
Previously treated locally advanced and unresectable or metastatic
non
-
2023-510537-28-00
5
2020-05-15
Multiple Myeloma
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2023-506783-14-00
5
2020-02-24
Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer